The incidence and number of deaths from non-tuberculous mycobacterial (NTM) disease have been increasing globally. NTM have become extremely antibiotic resistant and difficult to treat. Current treatment requires a multidrug therapy comprising at least three antibiotics with a duration from six months to years. The prognosis is poor due to antibiotic resistance. A novel regimen consists of new drugs without resistant problem are urgently needed for the treatment of NTM. TenNor is currently pursuing multiple promising series of compounds with potential to become part of the novel regimen for the treatment of NTM diseases.